Biopharmx Corp (NYSE:BPMX) major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $0.20, for a total transaction of $59,278.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Biopharmx Corp (NYSE BPMX) traded up $0.01 during midday trading on Monday, reaching $0.19. The company’s stock had a trading volume of 1,067,336 shares, compared to its average volume of 1,620,000. Biopharmx Corp has a 52-week low of $0.16 and a 52-week high of $0.90.

Biopharmx Corp (NYSE:BPMX) last released its quarterly earnings results on Wednesday, September 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.06). The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Biopharmx Corp had a negative return on equity of 5,749.08% and a negative net margin of 22,005.88%.

ILLEGAL ACTIVITY NOTICE: “Biopharmx Corp (BPMX) Major Shareholder Vivo Capital Viii, Llc Sells 296,394 Shares” was published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at

A number of analysts recently issued reports on the stock. Maxim Group reissued a “buy” rating and set a $1.50 target price (down previously from $3.00) on shares of Biopharmx Corp in a research report on Wednesday, September 13th. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Biopharmx Corp in a research report on Tuesday, September 19th.

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with's FREE daily email newsletter.